Research ArticleAccepted Article
The inverse OARSI-OMERACT criteria is a valid indicator of the clinical worsening of knee osteoarthritis: data from the Osteoarthritis Initiative
Jeffrey B. Driban, Matthew S. Harkey, Lori Lyn Price, Grace H. Lo and Timothy E. McAlindon
The Journal of Rheumatology June 2020, jrheum.200145; DOI: https://doi.org/10.3899/jrheum.200145
Jeffrey B. Driban
From the Division of Rheumatology, Allergy, and Immunology; Tufts Medical Center; Boston MA; USA; Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester MA, USA; The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston MA, USA; Tufts Clinical and Translational Science Institute, Tufts University, Boston MA, USA; Medical Care Line and Research Care Line, Houston Health Services Research and Development (HSR&D) Center of Excellence Michael E. DeBakey VAMC, Houston TX, USA; Section of Immunology, Allergy, and Rheumatology; Baylor College of Medicine; Houston TX; USA. These analyses were financially supported by a public-private partnership comprised of five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories; Novartis Pharmaceuticals Corporation, GlaxoSmithKline; and Pfizer, Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This manuscript was prepared using an OAI public use data set and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners. The project described was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, Award Number UL1TR002544. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This work was also supported in part by the Houston Veterans Affairs Health Services Research and Development Center of Excellence (HFP90-020). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. MSH was financially supported by a grant from the National Institutes of Health (grant no. 5 TL1 TR 1454-3). Address correspondence to Jeffrey Driban, PhD, ATC, CSCS; Division of Rheumatology, Tufts Medical Center; 800 Washington Street, Box 406, Boston, MA 02111; Phone: 617-636-7449; Fax: 617-636-1542; Email: jeffrey.driban@tufts.edu
Matthew S. Harkey
From the Division of Rheumatology, Allergy, and Immunology; Tufts Medical Center; Boston MA; USA; Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester MA, USA; The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston MA, USA; Tufts Clinical and Translational Science Institute, Tufts University, Boston MA, USA; Medical Care Line and Research Care Line, Houston Health Services Research and Development (HSR&D) Center of Excellence Michael E. DeBakey VAMC, Houston TX, USA; Section of Immunology, Allergy, and Rheumatology; Baylor College of Medicine; Houston TX; USA. These analyses were financially supported by a public-private partnership comprised of five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories; Novartis Pharmaceuticals Corporation, GlaxoSmithKline; and Pfizer, Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This manuscript was prepared using an OAI public use data set and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners. The project described was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, Award Number UL1TR002544. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This work was also supported in part by the Houston Veterans Affairs Health Services Research and Development Center of Excellence (HFP90-020). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. MSH was financially supported by a grant from the National Institutes of Health (grant no. 5 TL1 TR 1454-3). Address correspondence to Jeffrey Driban, PhD, ATC, CSCS; Division of Rheumatology, Tufts Medical Center; 800 Washington Street, Box 406, Boston, MA 02111; Phone: 617-636-7449; Fax: 617-636-1542; Email: jeffrey.driban@tufts.edu
Lori Lyn Price
From the Division of Rheumatology, Allergy, and Immunology; Tufts Medical Center; Boston MA; USA; Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester MA, USA; The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston MA, USA; Tufts Clinical and Translational Science Institute, Tufts University, Boston MA, USA; Medical Care Line and Research Care Line, Houston Health Services Research and Development (HSR&D) Center of Excellence Michael E. DeBakey VAMC, Houston TX, USA; Section of Immunology, Allergy, and Rheumatology; Baylor College of Medicine; Houston TX; USA. These analyses were financially supported by a public-private partnership comprised of five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories; Novartis Pharmaceuticals Corporation, GlaxoSmithKline; and Pfizer, Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This manuscript was prepared using an OAI public use data set and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners. The project described was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, Award Number UL1TR002544. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This work was also supported in part by the Houston Veterans Affairs Health Services Research and Development Center of Excellence (HFP90-020). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. MSH was financially supported by a grant from the National Institutes of Health (grant no. 5 TL1 TR 1454-3). Address correspondence to Jeffrey Driban, PhD, ATC, CSCS; Division of Rheumatology, Tufts Medical Center; 800 Washington Street, Box 406, Boston, MA 02111; Phone: 617-636-7449; Fax: 617-636-1542; Email: jeffrey.driban@tufts.edu
Grace H. Lo
From the Division of Rheumatology, Allergy, and Immunology; Tufts Medical Center; Boston MA; USA; Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester MA, USA; The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston MA, USA; Tufts Clinical and Translational Science Institute, Tufts University, Boston MA, USA; Medical Care Line and Research Care Line, Houston Health Services Research and Development (HSR&D) Center of Excellence Michael E. DeBakey VAMC, Houston TX, USA; Section of Immunology, Allergy, and Rheumatology; Baylor College of Medicine; Houston TX; USA. These analyses were financially supported by a public-private partnership comprised of five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories; Novartis Pharmaceuticals Corporation, GlaxoSmithKline; and Pfizer, Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This manuscript was prepared using an OAI public use data set and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners. The project described was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, Award Number UL1TR002544. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This work was also supported in part by the Houston Veterans Affairs Health Services Research and Development Center of Excellence (HFP90-020). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. MSH was financially supported by a grant from the National Institutes of Health (grant no. 5 TL1 TR 1454-3). Address correspondence to Jeffrey Driban, PhD, ATC, CSCS; Division of Rheumatology, Tufts Medical Center; 800 Washington Street, Box 406, Boston, MA 02111; Phone: 617-636-7449; Fax: 617-636-1542; Email: jeffrey.driban@tufts.edu
Timothy E. McAlindon
From the Division of Rheumatology, Allergy, and Immunology; Tufts Medical Center; Boston MA; USA; Department of Population and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester MA, USA; The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston MA, USA; Tufts Clinical and Translational Science Institute, Tufts University, Boston MA, USA; Medical Care Line and Research Care Line, Houston Health Services Research and Development (HSR&D) Center of Excellence Michael E. DeBakey VAMC, Houston TX, USA; Section of Immunology, Allergy, and Rheumatology; Baylor College of Medicine; Houston TX; USA. These analyses were financially supported by a public-private partnership comprised of five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories; Novartis Pharmaceuticals Corporation, GlaxoSmithKline; and Pfizer, Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This manuscript was prepared using an OAI public use data set and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners. The project described was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, Award Number UL1TR002544. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This work was also supported in part by the Houston Veterans Affairs Health Services Research and Development Center of Excellence (HFP90-020). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. MSH was financially supported by a grant from the National Institutes of Health (grant no. 5 TL1 TR 1454-3). Address correspondence to Jeffrey Driban, PhD, ATC, CSCS; Division of Rheumatology, Tufts Medical Center; 800 Washington Street, Box 406, Boston, MA 02111; Phone: 617-636-7449; Fax: 617-636-1542; Email: jeffrey.driban@tufts.edu
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Accepted manuscript
The inverse OARSI-OMERACT criteria is a valid indicator of the clinical worsening of knee osteoarthritis: data from the Osteoarthritis Initiative
Jeffrey B. Driban, Matthew S. Harkey, Lori Lyn Price, Grace H. Lo, Timothy E. McAlindon
The Journal of Rheumatology Jun 2020, jrheum.200145; DOI: 10.3899/jrheum.200145
Accepted manuscript
The inverse OARSI-OMERACT criteria is a valid indicator of the clinical worsening of knee osteoarthritis: data from the Osteoarthritis Initiative
Jeffrey B. Driban, Matthew S. Harkey, Lori Lyn Price, Grace H. Lo, Timothy E. McAlindon
The Journal of Rheumatology Jun 2020, jrheum.200145; DOI: 10.3899/jrheum.200145